Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -2.08%33 PB Ratio is 17.41 as of Jul. 14, 2026, which is 34% above its 10-year median of 13.00. GuruFocus rates ASX:ILA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Island Pharmaceuticals ranks worse than 92.59% on this metric.
Island Pharmaceuticals Ltd stock PB Ratio (=17.41) is close to 3-year high of 18.75.
The historical rank and industry rank for Island Pharmaceuticals's PB Ratio or its related term are showing as below:
ASX:ILA'
s PB Ratio Range Over the Past 10 Years
Min: 4.83 Med: 13 Max: 18.75
Current: 17.41
During the past 5 years, Island Pharmaceuticals's highest PB Ratio was 18.75. The lowest was 4.83. And the median was 13.00.
ASX:ILA's PB Ratio is ranked worse than 92.59% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs ASX:ILA: 17.41
During the past 12 months, Island Pharmaceuticals's average Book Value Per Share Growth Rate was 150.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.10% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Island Pharmaceuticals was -15.10% per year. The lowest was -45.20% per year. And the median was -30.15% per year.
Back to Basics: PB Ratio
Island Pharmaceuticals (ASX:ILA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Island Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Island Pharmaceuticals (ASX:ILA) has a PB Ratio of 17.41 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Island Pharmaceuticals and its competitors. This is 34% above median its historical median of 13.00. Over the past decade, Island Pharmaceuticals' PB Ratio has ranged from 4.83 to 18.75. According to the industry distribution chart, Island Pharmaceuticals ranks #1137 out of 1228 companies in the Biotechnology industry, placing it in the top 92.6%.
Is Island Pharmaceuticals' PB Ratio too high?
Island Pharmaceuticals' current PB Ratio of 17.41 is 34% above median its 10-year median of 13.00. Over the past 10 years, this metric has ranged from a low of 4.83 to a high of 18.75. The Biotechnology industry median PB Ratio is 2.89. Island Pharmaceuticals' value of 17.41 is 503.5% above this industry median. Based on the distribution chart, Island Pharmaceuticals ranks #1137 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Island Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #1137 out of 1228 companies for PB Ratio. This places Island Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.89. Island Pharmaceuticals' value of 17.41 is 503.5% above this benchmark. Historically, Island Pharmaceuticals' own PB Ratio has ranged from 4.83 to 18.75 over the past decade. While the company's 10-year median is 13.00 vs. the industry median of 2.89, Island Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Island Pharmaceuticals's current PB Ratio of 17.41 is 503.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current PB Ratio is 17.41, which is 34% above median its own 10-year median of 13.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current PB Ratio of 17.41. The current PB Ratio is 17.41, which is 34% above median its 10-year median of 13.00 and 503.5% above the Biotechnology industry median of 2.89. Island Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current PB Ratio is 17.41 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
33GF Score
Get the complete analysis for ASX:ILA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
